Journal article

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study

Hang Quach, Darrell White, Andrew Spencer, P Joy Ho, Divaya Bhutani, Mike White, Sandeep Inamdar, Chris Morris, Ying Ou, Martin Gyger

CANCER CHEMOTHERAPY AND PHARMACOLOGY | SPRINGER | Published : 2017

University of Melbourne Researchers

Grants

Funding Acknowledgements

This study was supported by Amgen Inc. Medical writing and editorial assistance was provided by BlueMomentum, an Ashfield Company, part of UDG Healthcare PLC, and funded by Amgen Inc. HQ received research funding from, and is a member of scientific advisory committees for, Amgen.